Stifel Financial Corp Sells 2,044 Shares of uniQure (NASDAQ:QURE)

Stifel Financial Corp lowered its position in shares of uniQure (NASDAQ:QURE) by 3.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 60,996 shares of the biotechnology company’s stock after selling 2,044 shares during the period. Stifel Financial Corp owned about 0.13% of uniQure worth $301,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. RTW Investments LP acquired a new stake in shares of uniQure during the third quarter valued at about $49,000. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares during the last quarter. Atria Investments Inc acquired a new stake in uniQure during the 3rd quarter worth approximately $53,000. Quarry LP bought a new stake in uniQure during the 3rd quarter worth approximately $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its position in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,306 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Performance

Shares of QURE stock opened at $17.50 on Friday. The firm has a 50 day moving average of $9.26 and a 200-day moving average of $7.19. The company has a market cap of $853.00 million, a price-to-earnings ratio of -3.53 and a beta of 0.89. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52 week low of $3.73 and a 52 week high of $18.12.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, equities analysts forecast that uniQure will post -3.82 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on QURE. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Cantor Fitzgerald lifted their target price on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. Royal Bank of Canada increased their price target on uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Mizuho lifted their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. Finally, Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $33.88.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.74% of the stock is owned by company insiders.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.